Active Pharmaceutical Ingredient Industry - Major Leaders and Their Contribution to Global Revenue

The study involved four major activities to estimate the current size of the global active pharmaceutical ingredient market. Exhaustive secondary research was done to collect information on the market, its peer markets, and its parent market.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Market Size Estimation:

Both top-down and bottom-up approaches were used to estimate and validate the total size of the global active pharmaceutical ingredient market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry and markets have been identified through extensive secondary research.

# The revenue generated from the sale of active pharmaceutical ingredients by leading players has been determined through primary and secondary research.

# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263

The global APIs market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market.

Acquisitions and collaborations have been the key growth strategies adopted by players from 2016 to 2018.

Some of the leading players who adopted these strategies include Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), and Bristol-Myers Squibb (US).

Key Questions addressed by the report:

# Where will all these developments take the industry in the mid to long term?

# What types of annual and multi-year partnerships are API companies exploring?

# Which are the key players in the market and how intense is the competition?

# Which are the recent contracts and agreements key players have signed?

# What are the recent trends affecting the API manufacturers?

Pfizer is one of the leading players in the APIs market. The leading position of the company is majorly attributed to its exhaustive product portfolio. The company has a strong brand image, which gives it a competitive edge over other players. In order to remain competitive and strengthen its market position, the company primarily focuses on adopting both organic and inorganic growth strategies such as agreements, partnerships, collaborations, product approvals, and acquisitions.

Novartis is another leading player in the APIs market. Its leading position can be attributed to its strong brand recognition and robust product portfolio. In order to maintain its leading position, the company invests a significant amount of its revenue in R&D activities. The significant investment in R&D enables the company to launch innovative and technologically advanced products in the market.

Recent Developments:

# In January 2018, Pfizer entered into a collaboration with Sangamo Therapeutics, Inc. (US) for the development of a potential gene therapy to treat amyotrophic lateral sclerosis (ALS).

# In May 2018, Novartis acquired AveXis, a clinical-stage gene therapy company, to develop a gene-based treatment for spinal muscular atrophy.

# In January 2018, Sanofi acquired Ablynx, a biopharmaceutical company to strengthen its platform for growth in rare blood disorders.

# In January 2018, Sanofi and Alnylam Pharmaceuticals, Inc. (US) announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize the development and commercialization of products prescribed for the treatment of rare genetic diseases.

Sanofi is one of the top players in the global APIs market. The leading position of the company is majorly attributed to its exhaustive product portfolio. The company manufactures APIs through its Sanofi Active Ingredient Solutions portfolio, which provides custom synthesis and API contract manufacturing services. The company pursues various growth strategies to strengthen its position in the APIs market. For instance, in July 2016, Sanofi Pasteur, a business unit of Sanofi, entered into an agreement with the Walter Reed Army Institute of Research (WRAIR) (US) to develop the Zika vaccine.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=263

Boehringer Ingelheim is one of the leading players in the global APIs market. Boehringer Ingelheim’s leading position in the APIs market can be attributed to its exhaustive product portfolio. The company is focused on developing innovative therapies to prolong patient’s lives. Its Prescription Medicines segment is engaged in the development and launch of APIs. In order to remain competitive and further strengthen its market position, the company adopts and implements organic and inorganic growth strategies, such as agreements, partnerships, approvals, alliances, and collaborations.

Bristol-Myers Squibb is a prominent player in the APIs market and holds expertise in the area of pharmaceutical ingredients. The company has a broad product portfolio in biologics, which serves as an important factor for its future growth, especially in the biopharmaceuticals market. In order to maintain its leadership position in the market, the company focuses on growth strategies, such as partnerships and expansions. 

Healthcare IT Market – Global Industry Dynamics

Major Objectives of this Study:

#  To define, describe, and forecast the healthcare IT market based on product & service, component, end user, and region.

# To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges).

# To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market.

# To analyze opportunities in the market for stakeholders and to provide details of the competitive landscape for market leaders.

# To forecast the size of the healthcare IT market with respect to five geographic regions – North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East and Africa.

# To profile key players in the healthcare IT market and comprehensively analyze their core competencies and market shares.

# To track and analyze competitive developments such as agreements, partnerships, and collaborations; mergers and acquisitions; new product/technology/service launches and upgrades; and research and development activities of leading players in the healthcare IT market

Download PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=252

The healthcare IT market is projected to reach USD 390.7 billion by 2024 from USD 187.6 billion in 2019, at a CAGR of 15.8% during the forecast period

The demand for healthcare IT solutions and services is driven by government mandates & support for healthcare IT solutions, rising use of big data in healthcare, high returns on investment for healthcare IT solutions, and the need to curtail escalating healthcare costs.

Key Questions Addressed in the Report:

# Who are the top 10 players operating in the healthcare IT market?

# What are the driving factors, restraints, opportunities, and challenges in the market?

# What are the industry trends as well as the current scenario in the healthcare IT market?

# What are the growth trends in the market at the segmental and overall market levels?

“North America dominated the Healthcare IT market in 2018”

The Healthcare IT market is broadly segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the Healthcare IT market in 2018.

Although, the global healthcare IT market is largely fragmented in nature with presence of number of small and mid-sized vendors operating at local and regional levels, Cerner Corporation (US), Optum (US), Cognizant (US), Philips Healthcare (Netherlands) and Epic Systems (US) are some of the leaders in the healthcare IT solutions market.

Recent Developments:

# In 2019, Philips launched Cares Aging & Caregiving service.

# In 2018, Change Healthcare launched Dx Gap Advisor.

# In 2017, Optum acquired DaVita Medical Group (US). The acquisition of DaVita enhanced Optum’s physician-led primary, specialty, in-home, and surgery-care delivery services business.

# In 2017, Cognizant acquired TMG Health (US) to expand its business process-as-a-service solutions for government and public health programs.

# In 2018, Optum collaborated with Humana (US), MultiPlan (US) and Quest Diagnostics (US) to form a group to explore the blockchain technology to improve data quality and reduce administrative costs in healthcare.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=252

Market Size Estimation:

Both top-down and bottom-up approaches were used to estimate and validate the total size of the healthcare IT market. These methods were also used to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry and markets have been identified through extensive secondary research.

# The industry’s market size, in terms of value, has been determined through primary and secondary research.

# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.urce=prnewswire&utm_medium=referral&utm_campaign=paidpr

Fertility Test Market - Global Leaders & Growth Strategies Adopted by Them

The global fertility test market is projected to reach USD 583.1 million by 2023 from USD 411.8 million in 2018, at a CAGR of 7.2%.

Key Questions Addressed by the Report:

# What are the growth opportunities related to the adoption of fertility test products across major regions in the future?

# Emerging countries have immense opportunities for the growth and adoption of ovulation prediction kits. Will this scenario continue in the next five years?

# Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?

# How will the increasing use of ovulation tracking mobile apps and fertility-tracking websites affect the growth of the market?

Growth in the fertility test market can be attributed to factors such as the increasing first-time pregnancy age in women, declining fertility rate among men and women, growing number of women suffering from disorders such as PCOS, emergence of advanced ovulation monitors, and increased awareness of fertility testing in both developed as well as developing countries.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139945432

On the other hand, the unproven accuracy of urine-based ovulation monitors in women suffering from PCOS and the lesser precision to confirm ovulation using ovulation prediction kits are the factors that are expected to restrain market growth to a certain extent during the forecast year.

Analysis of the market developments between 2015 and 2018 revealed that several growth strategies such as product launches, enhancements, and strategic acquisitions were adopted by the market players to strengthen their product portfolios and maintain a competitive position in the fertility test market. Among these business strategies, product launches was the most widely adopted growth strategies by the players in the fertility test market.

Recent Developments:

# In 2017, Swiss Precision Diagnostics (Switzerland) launched its Clearblue Connected Ovulation Test System.

# In 2017, NFI Consumer Healthcare (US) a division of Gregory Pharmaceutical Holdings (US) completed the acquisition of e.p.t over-the-counter pregnancy test kit brand from Prestige Brands Holdings.

# In 2017, Fairhaven Health (US), launched TempCue, a basal body temperature (BBT) thermometer.

# In 2016, Fertility Focus (UK) launched OvuSense App.

Swiss Precision Diagnostics (Switzerland) held the leading position in the global fertility test market in 2017. The company is one of the leading manufacturers and suppliers of fertility/ovulation tests for women. Clearblue is the flagship product of the company and has a very strong brand presence in countries such as the US, the UK, and Europe. 

Along with this, the company’s wide distribution network and innovative marketing strategies are the key factors contributing to its dominant share in the market. With the aim to maintain its dominant share in this highly competitive market, SPD focuses on product launches as its key growth strategy.

Church & Dwight (US) held the second position in the global fertility test market, in 2017. The company has a strong geographic presence with subsidiaries across seven countries including the UK, France, Germany, Canada, Mexico, Australia, and Brazil. Church & Dwight provides its fertility testing products to a large customer base through its wide distribution across 130 countries. 

The company is focusing its efforts to increase awareness about issues related to infertility and help women understand their reproductive health and fertile window to improve conception rate. Church & Dwight is expected to witness growth in the coming years due to its multiple initiatives to create awareness regarding fertility.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=139945432

North America is expected to dominate the fertility test market during the forecast period.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share of the global fertility test market during the forecast period (2018-2023).

The large share can be attributed to the growing use of fertility monitoring devices for contraception and rising awareness about the benefits of ovulation monitors through social media, marketing campaigns, and e-commerce sites. In addition, the emergence of advanced easy-to-use fertility monitors with high accuracy is one of the key factors propelling the growth of the fertility test market in North America.

Veterinary Pain Management Market - Major Industry Leaders & Their Contribution to Global Revenue Growth

Years considered for this report:

# 2017 – Base Year

# 2018 – Estimated Year

# 2023 – Projected Year

The veterinary pain management market is projected to reach USD 1.66 Billion by 2023 from USD 1.13 Billion in 2018, at a CAGR of 8.0% during the forecast period.

Factors such as growth in companion animal adoption, increasing number of veterinary practitioners and their rising income levels in developed economies, growing prevalence of animal disease causing pain and inflammation, and the rising adoption of pet insurance with growing animal health expenditure are expected to drive the growth of the market.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96167677

Target Audience:

# Healthcare institutions (hospitals, medical schools, and outpatient clinics)

# Market research and consulting firms

# Venture capitalists and investors

# Research & development companies

# Veterinary pain management manufacturers and distributors

The global veterinary pain management drugs market is a consolidated market, and the top three pharmaceutical companies account for a large share of the global market. Boehringer Ingelheim (Germany), Zoetis (US), Elanco (US), dominated the veterinary pain management drugs market in 2017.

Boehringer Ingelheim:

Boehringer Ingelheim held the largest share of global veterinary pain management drugs market in 2017. The company has a strong portfolio of pharmaceutical products that focus on the treatment of chronic diseases in companion animals. For instance, it manufactures and markets Metacam, one of the best-selling pain management drugs used in companion animals to cure osteoarthritis. To sustain its leading position in the market, the company adopted several growth strategies such as expansions, agreements, and partnerships. For example, in 2016, the company opened its new R&D facility at the Iowa State University Research Park in Ames (US).

Zoetis:

Zoetis held the second position in the global veterinary pain management drugs market in 2017. It offers widely adopted pain management drugs for companion animals such as cats, dogs, and horses. It is the manufacturer and supplier of Rimadyl, one the best-selling pain management drug brand for dogs. The company focuses on investing in R&D activities in order to maintain and enhance its position in the market. In 2016, the company invested USD 376 million in R&D, which accounts for 8% of its total revenue. Zoetis also focuses on expansions and mergers & acquisitions to improve its product offerings and production capabilities. For example, in 2015, Zoetis established a manufacturing facility in Lincoln, US, to improve production capabilities for animal health products and offer a wider range of animal health products to veterinarians, livestock producers, and pet owners.

Elanco:

Elanco held the third position in veterinary pain management drugs market. Elanco has a vast geographical presence in all major markets. It has offices and research centers at multiple locations within the Americas, Europe, the Middle East and Africa, and Asia Pacific. Elanco primarily pursues the strategy of product launches to increase its share in the veterinary pain management market for example, the company launched Galliprant and Onisor in 2017 & 2016 respectively. The company also adopts inorganic growth strategies such as acquisitions and collaborations to improve its position in the market, like the acquisition of Novartis Animal Health in 2015. 

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=96167677

APAC is expected to grow at the highest CAGR during the forecast period.

Global veterinary pain management market has been studied for North America, Europe, Asia Pacific (APAC), Latin America, and Middle East & Africa. APAC is expected to grow at the highest CAGR in veterinary pain management market, primarily due to the significant growth in pet adoption, increasing awareness about animal health, and growing per capita animal health expenditure, especially in India and China.

Bioprocess Validation Market - Expected Growth in Revenue, Globally

The report “Bioprocess Validation Market by Test Type (Extractables and Leachables, Integrity Testing, Microbiology Testing), Process Component (Filter Element, Bioreactors), End-User (CDMO, Biotechnology & Pharmaceutical Companies) - Global Forecast to 2024", is exceeded USD 180 million in 2019 and is projected to be valued over USD 360 million by 2024, at a CAGR of 14.6% during the forecast period.

The stringent safety and quality regulations governing product certification and testing across the biopharmaceutical and pharmaceutical industries, high demand for the outsourcing of bioprocess validation services and rising R&D spending in the life science are some of the major factors that are expected to drive the growth of this market during the forecast period.

Additionally, automation in bioprocess validation services and geographic expansions by market players are the upcoming trends in bioprocess validation, which also expected to support market growth in the coming years.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39981433

Recent Developments:

# In August 2018, Merck KGaA launched the BioReliance Product Characterization Portfolio to enhance its service portfolio in the bioprocess validation market.

# In March 2017, Toxikon and SG Lab (Italy) entered into a partnership, to extend its analytical and extractable & leachable testing service portfolio to determine the drug integrity in the entire life cycle.

# In January 2019, SGS acquired LeanSis Expertos en Productividad S.L. (Spain). This acquisition provided SGS operational and manufacturing training and capacity building services to over 200 clients across Spain.

# In February 2018, Pall Corporation expanded its Hoegaarden office in Belgium with new R&D center, customer demonstration labs, and manufacturing space. This will help the company to establish its position in the Belgium market.

Contract Development and Manufacturing Organizations (CDMOs) to form the fastest-growing end-user segment in the bioprocess validation market

Among all end-user segments, the demand for bioprocess validation is estimated to grow at the highest rate among CDMOs. This can majorly be attributed to the stringent FDA safety regulations and consumer lawsuits regarding testing requirement, accelerating costs of validation and quality check processes after or during drug development, increasing adoption of bioprocess validation services to keep biopharma production, and approvals in line with the regulatory requirements.

North America is estimated to be the largest regional market for bioprocess validation

North America is expected to account for the largest share of the bioprocess validation market in 2019, closely followed by Europe. Factors such as the presence of well-established biopharmaceutical industry in the region, high R&D expenditure, presence of leading bioprocess validation service providers, and stringent regulatory requirements for biopharmaceutical production are driving the growth of the bioprocess validation market in North America.

Critical questions the report answers:

# Where will all these developments take the industry in the medium-to-long-term?

# What are the major trends in bioprocess validation?

# Who are the major end-users of bioprocess validation?

# Which test types are used mainly for bioprocess validation?

# Which process component has a higher adoption rate of bioprocess validation?

Request Sample Pages@  

https://www.marketsandmarkets.com/requestsampleNew.asp?id=39981433

The prominent players operating in the bioprocess validation market are Merck KGaA (Germany), Sartorius Stedim Biotech (Sartorius AG) (France), Pall Corporation (US), SGS S.A. (Switzerland), Eurofins Scientific (Luxembourg), Cobetter Filtration Equipment Co., Ltd. (China), Toxikon Corporation (US), DOC S.r.l. (Italy), MEISSNER FILTRATION PRODUCTS, INC. (US), and Thermo Fisher Scientific (US).

Cell Viability Assays Market - Global Leaders & Major Growth Strategies Adopted by Them

The global cell viability assays market is projected to reach USD 4.16 billion by 2023 from USD 2.78 billion in 2018, at a CAGR of 8.4%.

Factors such as rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research and rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics are driving the growth of this market.

Target Audience:

# Manufacturers of cell viability instruments and consumables

# Distributors of cell viability instruments and consumables

# Research and development organizations

# Hospitals and clinics

# Diagnostic centers

# Market research and consulting firms

# Venture capitalists and investors

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=5932511

The emerging markets are expected to provide growth opportunities for players operating in the cell viability assays market in the coming years. However, the high cost of instruments is expected to restrain the growth of this market to a certain extent during the forecast period.

Players in the global cell viability assays market, such as Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US), are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies of product launches, expansions, agreements, collaborations, and acquisitions.

Objectives of the Study:

# To define, describe, segment, and forecast the global cell viability assays market by product, application, cell type, end user, and region.

# To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges).

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of the cell viability assays market in five main regions (along with major countries) North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

# To profile key players in the global cell viability assays market and comprehensively analyze their core competencies and market shares.

# To track and analyze competitive developments such as mergers and acquisitions; new product/technology launches; expansions; collaborations and agreements; and R&D activities of the leading players in the global cell viability assays industry.

Thermo Fisher is the leading player in the cell viability assay kits market. The company offers a broad portfolio of cell viability assays for flow cytometers, microplates, biofilm imaging, along with other consumables ranging from reagents to stains and dyes. The company’s stronghold in the market is largely due to its strong product portfolio and strong customer relations and its strong sales and distribution network. It also leverages the advantage of three well-established brands Thermo Scientific, Fisher Scientific, and Unity Lab Services.

Additionally, its large number of production sites gives it a competitive advantage over other players in the cell viability assays market. The company’s extensive R&D activities enable it to increase its depth of capabilities in technologies, software, and services. Moreover, its significant investments in R&D enable it to provide innovative products in the market space, thus enabling it to maintain and improve its competitive position in the cell analysis market.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=5932511

Merck is the second-largest player in the global cell viability assay kits market in 2018. With a strong brand name and wide geographic coverage in more than 60 countries, Merck has a well-established presence in this market. This company is expected to witness high growth in this market by adopting various organic and inorganic growth strategies. With regard to providing innovative products, Merck invests a significant amount of its sales revenue in R&D. In 2017, it invested around 14% of its sales revenue into R&D.

This allows the company to extend its technological capabilities and provide superior-quality products, thereby helping it to achieve long-term growth. The company is also investing a large sum in its expansion projects to increase its production capacity and cater to a larger consumer base. In this regard, the company invested USD 19 million in its new manufacturing and distribution center for the Life Science business in India, in 2018. Similar investments have been made by the company in the last few years. The acquisition of Sigma-Aldrich significantly enhanced the company’s global presence and broadened its portfolio in the cell viability assays market.

Laparoscopic Surgery - Emerging Technological Innovations & Global Industry Dynamics

Objectives of the Study:

# To define, describe, and forecast the hernia mesh repair surgery market, by type of surgery and type of mesh fixator (glue & tack applicator).

# To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall laparoscopic surgery market.

# To forecast the size of the market segments with respect to specific countries.

# To profile the key players and comprehensively analyze their core competencies.

# To track and analyze competitive developments such as product launches; agreements, partnerships, and joint ventures; mergers and acquisitions; and research and development activities in the hernia mesh repair surgery market.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=260433127

The rising adoption of mesh in hernia repair surgeries, rising geriatric population, new product developments, and favorable reimbursement scenario in developed countries are the major factors driving the growth of this market.

The report analyzes and studies the patient population affected with hernia in the US, Canada, Germany, France, the UK, Italy, Spain, Japan, China, and India. Along with patient population, the report studies the adoption of open and laparoscopic hernia repair surgeries and the adoption of tack and glue applicators for mesh fixation.

Based on the type of hernia repair surgery, open hernia repair surgery accounted for the largest market share in 2017. Open hernia repair does not require any advanced equipment and takes 25% lesser time than laparoscopy. This makes open hernia repair more cost effective. Moreover, this type of surgery is preferred for hernias that have been present for a long period of time.

Based on the type of mesh fixator, glue applicators are expected to register the highest growth rate in the forecast period. The cost effectiveness, reduction in surgery time, and lower pain associated with glue fixation are driving the adoption of glue in hernia mesh fixation.

The US accounted for the largest share of the hernia mesh repair surgery market in 2017. The large share of the US is attributed to the large patient population, increasing adoption of technologically advanced products, and presence of a well-established medical reimbursement policy in the country.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=260433127

The major players in the hernia mesh repair surgery market profiled in this report are Medtronic (Ireland), Johnson & Johnson (US), B. Braun (Germany), C. R. Bard (US), and W.L. Gore (US).